Gilead Sciences stock trades at EUR 135.59, volume 17.2 percent above average
Published on 10/12/2026 at 15:47 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSKey points in brief
- Gilead Sciences stock traded at EUR 135.59 at Lang & Schwarz on October 12, 2026, up 1.46 percent versus the Xetra close of EUR 133.64.
- The EUR 168.5 billion market value and 2.00 percent P/E-adjusted dividend yield provide the valuation context.
- Morgan Stanley cut its target from USD 165.00 to USD 163.00 on October 7, 2026, while maintaining an overweight rating.
- Gilead Sciences is scheduled to report third-quarter 2026 results on October 22, 2026.
Gilead Sciences (ISIN US3755581036) was trading at EUR 135.59 at Lang & Schwarz on October 12, 2026 at 3:37 p.m. CEST, plus 1.46 percent versus the Xetra close of October 9, 2026 at EUR 133.64. The GIS.DE quote showed 907 shares traded against an average volume of 774 shares, a difference of 17.18 percent.
Stock remains below its yearly high
On Nasdaq, Gilead Sciences was trading at USD 151.62 at 9:46 a.m. EDT on October 12, 2026. The USD 114.02 to USD 157.29 52-week range placed the stock 3.61 percent below its high, while the Nasdaq quote was 23.16 percent higher year to date as of October 9, 2026.
The company is listed on Nasdaq under ticker GILD, according to Stock Analysis. The profile identifies Gilead Sciences as a healthcare company in the drug manufacturers industry and confirms ISIN US3755581036.
Valuation and analyst targets
Gilead Sciences had a market capitalization of EUR 168.5 billion and a P/E ratio of minus 56.78 on the GIS.DE quote. The dividend yield was 2.17 percent, according to The Wall Street Journal on October 9, 2026.
MarketBeat reported on October 7, 2026 that Morgan Stanley cut its target from USD 165.00 to USD 163.00 while maintaining an overweight rating. The new target lies 7.50 percent above the USD 151.62 Nasdaq price.
October 22 results date
The Wall Street Journal listed October 22, 2026 as the next earnings date for third-quarter 2026 results. Its estimate section placed consensus earnings per share at USD 2.15 for that quarter.
Comparison with peers
Gilead Sciences: plus 1.46 percent, P/E minus 56.78, market capitalization EUR 168.5 billion
Vertex Pharmaceuticals (NASDAQ, USD): plus 0.52 percent, P/E 29.78, market capitalization USD 130.1 billion
Amgen (NASDAQ, USD): plus 0.17 percent, P/E 25.80, market capitalization USD 224.3 billion
Price and trading status
Gilead Sciences was trading at EUR 135.59 at Lang & Schwarz on October 12, 2026 at 3:37 p.m. CEST, plus 1.46 percent versus the Xetra close of October 9, 2026 at EUR 133.64. The Nasdaq quote placed the stock at USD 151.62 at 9:46 a.m. EDT on October 12, 2026.
The further course of trading is shown by the continuously updated real-time quote of Gilead Sciences stock.
Gilead Sciences market data
- Company: Gilead Sciences, Inc.
- ISIN: US3755581036
- Ticker: GILD
- Primary exchange: NASDAQ
- Price Lang & Schwarz (as of October 12, 2026, 3:37 p.m. CEST): EUR 135.59
- Change versus Xetra close: plus 1.46 percent
- Xetra close (October 9, 2026): EUR 133.64
- Market capitalization: EUR 168.5 billion (as of October 12, 2026)
- 52-week range: USD 114.02-157.29 (as of October 12, 2026)
- Sector / Industry: Healthcare / Drug Manufacturers - General
- Index membership: Nasdaq-100
- Next earnings date: October 22, 2026
Market context: Market report Nasdaq Composite.
